Preparation and application of anti-staphylococcus aureus IsdB antibody

By preparing the antibody IsdB-H6, which specifically binds to the iron-determining protein B on the surface of Staphylococcus aureus, the treatment challenge of multidrug-resistant MRSA infection has been solved, achieving effective inhibition of MRSA and reducing mortality.

CN120943954AActive Publication Date: 2025-11-14CHONGQING YUANLUN BIOTECH
4 Cites 2 Cited by

Patent Information

Application Number
CN202511494184.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-20
Publication Date
2025-11-14
Estimated Expiration
2045-10-20

AI Technical Summary

Technical Problem

Current antibiotic treatments for Staphylococcus aureus infections, especially multidrug-resistant MRSA infections, are ineffective, have high mortality rates, and multidrug-resistant strains account for a large proportion of hospital and community infections.

Method used

An antibody, IsdB-H6, specifically binding to Staphylococcus aureus iron ion surface determinant B, including the CDR region of the heavy and light chain variable regions, was prepared for use in the preparation of products for the diagnosis or treatment of diseases related to Staphylococcus aureus infection.

Benefits of technology

IsdB-H6 antibody can inhibit the growth of Staphylococcus aureus in a low-iron environment and resist the systemic invasion of MRSA, showing good prospects for clinical application.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses preparation and application of an anti-staphylococcus aureus IsdB antibody. The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 8; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 16. The invention also provides nucleic acid for coding the antibody, a vector containing the nucleic acid and a cell containing the vector. In addition, experiments prove that the antibody can inhibit systemic infection of MRSA and resist invasion of MRSA to pneumonia, and has a good clinical application prospect.
Need to check novelty before this filing date? Find Prior Art